MedTrace Logo

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

NCT05248048 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-02-21

No results posted yet for this study

Summary

Evaluate the clinical safety and feasibility of NKG2D CAR-T administrated by hepatic artery transfusion for patients with previously treated liver metastatic colorectal cancer.

Conditions

  • Refractory Metastatic Colorectal Cancer

Interventions

BIOLOGICAL

CAR-T infusion

NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer

Sponsors & Collaborators

  • Hangzhou Cheetah Cell Therapeutics Co., Ltd

    collaborator OTHER

  • The Third Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Xuehu Xu, MD · The Third Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05248048 on ClinicalTrials.gov